ワタナベ エリ   WATANABE Eri
  渡邉 絵里
   所属   医学部 医学科(東京女子医科大学病院)
   職種   助教
言語種別 英語
発表タイトル Cardiac Magnetic Resonance T1 Mapping and Late Gadolinium Enhancement Surrogate Major Cardiac Events in Systemic Sclerosis
会議名 The 83rd Annual Scientific Meeting of the Japanese Circulation Society (JCS2019)
主催者 Japanese Circulation Society
学会区分 全国規模の学会
発表形式 ポスター掲示
講演区分 一般
発表者・共同発表者◎SAKAI Akiko, NAGAO Michinobu, NAKAO Risako, WATANABE Eri, SAKAI Shuji, HAGIWARA Nobuhisa
発表年月日 2019/03/30
開催地
(都市, 国名)
Yokohama, JAPAN
概要 *Poster Session (English) 37 CT MRI Myocardium
Introduction: Systemic sclerosis (SSC) is an autoimmune disease that progresses interstitial fibrosis in the systemic organs. In SSC, cardiac involvement causes myocardial fibrosis, leading to ventricular tachycardia (VT) and the worsening of heart failure. However, the prediction indicator is unknown. We investigate whether myocardial fibrosis by cardiac magnetic resonance (CMR) T1 mapping and late gadolinium enhancement (LGE) could be a surrogate marker for major adverse cardiac events (MACE) in patients with SSC. Methods: Thirty-two patients (mean age, 60 years; 29 women) with SSC underwent CMR for the assessment of cardiac function and myocardial fibrosis. The presence of LGE was evaluated in all patients. The extracellular volume fraction (ECV, %) for mid-left ventricular septum was derived from T1 mapping in sixteen patients. MACE was defined as cardiac death, VT or heart failure hospitalization. Results: MACE was observed in 8 (25%) patients for mean follow-up period of 36 months. The presence of LGE was seen in 6 patients with MACE (75%) and 4 patients without MACE (17%), and the frequency is significant higher in patients with MACE (p <0.05). ECV was significantly greater for patients with MACE than those without (40 ± 10% vs. 28 ± 5%, p< 0.05). Receiver operating curve analysis revealed that the area under the curves of the optimal ECV of 0.33 and the presence of LGE for prediction of MACE were 0.92 and 0.79, respectively. Conclusion: ECV and the presence of LGE can be used as surrogate markers for MACE in patients with SSC.